NCT07415031ClinicalTrials.gov
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
En bref
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC)…
Phase 2170 participants recherchés101 sites21 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT07415031Ouvrir cette fiche sur ClinicalTrials.govSynchronisé la semaine dernière
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-02-17; recorded start 2026-05-06
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Mirati Therapeutics Inc.)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Allocation not stated in the record
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 100 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 170 participants (target), run at 101 sites, across 21 countries.
How this score is built
- Enrolment21/40
170 participants (target)
- Site count23/25
100 sites
- Country count15/15
20 countries
- Planned duration7/10
Planned over about 22 months
- Sponsor scale4/10
Mirati Therapeutics Inc. has led 19 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Affections
- Solid Tumors
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – Aucun maximum |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 2 |
| Répartition | Sans objet |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | NONE (0) |
| Recrutement | 170 participants recherchés |
Promoteur et collaborateurs
- Mirati Therapeutics Inc. Promoteur
Groupes et interventions
- Arm A1EXPERIMENTAL
- Arm A2EXPERIMENTAL
- Arm B1EXPERIMENTAL
- Arm B2EXPERIMENTAL
- Arm B3EXPERIMENTAL
- Arm B4EXPERIMENTAL
- Arm C1EXPERIMENTAL
- Arm C2EXPERIMENTAL
- Arm C3EXPERIMENTAL
- Arm C4EXPERIMENTAL
Interventions
- Médicament Adagrasib
Specified dose on specified days
- Médicament Cetuximab
Specified dose on specified days
- Médicament Docetaxel
Specified dose on specified days
- Médicament Fluorouracil
Specified dose on specified days
- Médicament Irinotecan
Specified dose on specified days
- Médicament Leucovorin
Specified dose on specified days
- Médicament Oxaliplatin
Specified dose on specified days
- Médicament Pembrolizumab
Specified dose on specified days
- Médicament Pemetrexed
Specified dose on specified days
Critères de jugement
Critère de jugement principal
Number of Participants With Adverse Events (AEs)
Délai Up to 90 days from last dose or study discontinuation
Critère de jugement principal
Number of Participants With AEs Leading to Treatment Discontinuation
Délai Up to 90 days from last dose or study discontinuation
Critère de jugement principal
Number of Participants With Serious Adverse Events (SAEs)
Délai Up to 90 days from last dose or study discontinuation
Critère de jugement principal
Number of Participants With AEs Leading to Death
Délai Up to 90 days from last dose or study discontinuation
Dates
| Date de début | 6 mai 2026 (réelle) |
|---|---|
| Achèvement principal | 16 février 2028 (estimée) |
| Achèvement | 16 février 2028 (estimée) |
| Première publication | 17 février 2026 (réelle) |
| Dernière mise à jour | 12 novembre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | novembre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
81 sites sont en recrutement
Australia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Local Institution - 0093 | St Leonards | New South Wales | Retiré |
Belgium
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| AZ Maria Middelares | Ghent | En recrutement |
Brazil
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Clinical Oncology | São Paulo | En recrutement | |
| Fundacao Antonio Prudente - AC Camargo Cancer Center | São Paulo | En recrutement |
Canada
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| BC Cancer - Vancouver | Vancouver | British Columbia | En recrutement |
China
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Local Institution - 0037 | Beijing | Beijing Municipality | Retiré |
| Local Institution - 0038 | Changsha | Hunan | Retiré |
| Local Institution - 0040 | Chengdu | Sichuan | Retiré |
| Local Institution - 0044 | Hangzhou | Zhejiang | Retiré |
| Local Institution - 0039 | Jinan | Shandong | Retiré |
| Local Institution - 0047 | Linyi | Shandong | Retiré |
| Local Institution - 0048 | Nanchang | Jiangxi | Retiré |
| Local Institution - 0046 | Nanjing | Jiangsu | Retiré |
| Local Institution - 0043 | Shanghai | Shanghai Municipality | Retiré |
| Local Institution - 0049 | Shenyang | Liaoning | Retiré |
| Local Institution - 0041 | Xi'an | Retiré | |
| Local Institution - 0045 | Xiamen | Fujian | Retiré |
| Local Institution - 0042 | Zhengzhou | Henan | Retiré |
France
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| ICO Papin | Angers | Maine-et-Loire | En recrutement |
| Chu Jean Minjoz | Besançon | Doubs | En recrutement |
| Hospices Civils de Lyon - Hopital Louis Pradel | Bron | Rhône | En recrutement |
| Centre Hospitalier Intercommunal de Créteil | Créteil | En recrutement | |
| L Hopital Nord Ouest | Gleizé | Rhône | En recrutement |
| Chu Grenoble Alpes | La Tronche | Isère | En recrutement |
| Assistance Publique Hôpitaux de Marseille - Hôpital Nord | Marseille | En recrutement | |
| Centre Hospitalier Universitaire de Nice - Hopital Pasteur | Nice | Alpes-Maritimes | En recrutement |
| Centre Antoine-Lacassagne | Nice | Alpes-Maritimes | En recrutement |
| Groupe hospitalier Paris saint Joseph | Paris | Île-de-France Region | En recrutement |
| CHU Bordeaux Haut-Leveque | Pessac | Aquitaine | En recrutement |
| Local Institution - 0051 | Poitiers | Vienne | Retiré |
| Centre Hospitalier de Cornouaille Quimper - Concarneau | Quimper | En recrutement | |
| Institut de Cancérologie de l'Ouest | Saint-Herblain | Loire-Atlantique | En recrutement |
| Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes | Saint-Herblain | Loire-Atlantique | En recrutement |
| Hôpital d'Instruction des Armées Bégin | Saint-Mandé | En recrutement | |
| Nouvel Hôpital Civil (NHC) | Strasbourg | Alsace | En recrutement |
| Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau | Tours | En recrutement |
Germany
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Klinikum Neuperlach | München | En recrutement |
Greece
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Alexandra General Hospital of Athens | Athens | Attikí | En recrutement |
| Metropolitan Hospital | Attiki | En recrutement | |
| Theagenio Hospital | Thessaloniki | Kentrikí Makedonía | En recrutement |
Hungary
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Orszagos Koranyi Pulmonologiai Intezet | Budapest | En recrutement | |
| Orszagos Onkologiai Intezet | Budapest | En recrutement |
Israel
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Bnai Zion Medical Center | Haifa | En recrutement | |
| Shaare Zedek Medical Center | Jerusalem | Jerusalem | En recrutement |
| Tel Aviv Sourasky Medical Center - Oncology - Hematology/Oncology | Tel Aviv | En recrutement |
Italy
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola | Bologna | En recrutement | |
| Azienda Ospedaliera Universitaria Careggi | Florence | Tuscany | En recrutement |
| IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" | Meldola | Emilia-Romagna | En recrutement |
| Istituto Europeo di Oncologia IRCCS | Milan | En recrutement | |
| Istituto Europeo di Oncologia IRCCS | Milan | En recrutement |
51 sites supplémentaires sont indiqués dans la fiche du registre.
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 27 octobre 2026
Site retiré
1 site removed (101 total)
102101
- 9 octobre 2026
Site ajouté
2 sites added (102 total)
100102
- 18 août 2026
Site retiré
1 site removed (100 total)
101100
- 27 juillet 2026
Site ajouté
1 site added (101 total)
100101